Jacobs Levy Equity Management Inc. Grows Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Jacobs Levy Equity Management Inc. grew its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 51.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 290,011 shares of the biotechnology company's stock after buying an additional 98,285 shares during the period. Jacobs Levy Equity Management Inc. owned 1.36% of Enanta Pharmaceuticals worth $1,668,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $26,000. Tower Research Capital LLC TRC boosted its stake in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $58,000. Wells Fargo & Company MN grew its holdings in shares of Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after acquiring an additional 6,518 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth approximately $105,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock traded up $0.11 during trading hours on Tuesday, hitting $6.07. The company's stock had a trading volume of 148,323 shares, compared to its average volume of 285,076. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $17.24. The company has a market cap of $129.76 million, a PE ratio of -1.23 and a beta of 0.81. The business has a 50 day moving average price of $5.47 and a two-hundred day moving average price of $6.55.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The firm had revenue of $14.93 million during the quarter, compared to the consensus estimate of $15.96 million. As a group, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ENTA shares. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. Finally, JMP Securities reiterated a "market outperform" rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.